Results 61 to 70 of about 6,174 (184)

Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer [PDF]

, 2023
PURPOSE: The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with METHODS: In this ongoing, open-label, single-arm, phase II study, patients ...
et al.,, Morgensztern, Daniel, Riely, Gregory J   +2 more
core   +2 more sources

A preexisting rare PIK3CA e545k subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling [PDF]

, 2018
Combined MEK and CDK4/6 inhibition (MEKi + CDK4i) has shown promising clinical outcomes in patients with NRAS- mutant melanoma. Here, we interrogated longitudinal biopsies from a patient who initially responded to MEKi + CDK4i therapy but subsequently ...
Amaria, Rodabe N., Aplin, Andrew A., Carapeto, Fernando C.L., Chen, Merry, Chen, Pei-Ling, Davies, Michael A., Duose, Dzifa Y., Futreal, P. Andrew, Kwong, Lawrence N., Lazar, Alexander J., Li, Jun, Liang, Roger J., Liu, Mingguang, McQuade, Jennifer L., Roh, Whijae, Romano, Gabriele, Song, Ping, Teh, Jessica L.F., Wargo, Jennifer A., Zhang, David Y., Zhang, Jianhua   +20 more
core   +1 more source

EGR Proteins Mediate Interferon‐Independent Anti‐HSV‐1 Responses Through Viral and Host Targets

Advanced Science, Volume 13, Issue 13, 3 March 2026.
Early antiviral responses are typically mediated by interferons. However, during HSV‐1 infection, host early growth response (Egr) genes, which are not interferon‐stimulated genes, are quickly induced by viral protein ICP0. EGR proteins, in turn, suppress viral lytic infection by activating viral latency‐associated (LAT) and host immune regulatory ...
Shuaishuai Wang, Fujun Hou, Xunuo Jin, Yuhang Xiang, Dongli Pan   +4 more
wiley   +1 more source

Mapping genetic interactions in cancer: a road to rational combination therapies. [PDF]

, 2019
The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2 ...
Krogan, Nevan J, Tutuncuoglu, Beril
core  

A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Colorectal cancer (CRC) is a major health burden globally and in China, where 3%–5% of cases involve the BRAFV600E mutation, which is associated with aggressive disease and therefore a poor prognosis. Although the combination of encorafenib and cetuximab has demonstrated improved survival in BRAFV600E mutant metastatic CRC (mCRC ...
Wang Xicheng, Deng Yanhong, Zhang Yanqiao, Liu Tianshu, Yuan Xianglin, Yang Jianwei, Zhang Tao, Zang Aimin, Liu Yu, Huang Li, Ye Feng, Zong Hong, Ba Yi, Klauck Isabelle, Vedovato Jean‐Claude, Groc Mélanie, Guo Angela, Li Jian, Shen Lin   +18 more
wiley   +1 more source

The safety and efficacy of binimetinib for lung cancer: a systematic review

BMC Pulmonary Medicine
Background Lung cancer, accounting for a significant proportion of global cancer cases and deaths, poses a considerable health burden. Non-small cell lung cancer (NSCLC) patients have a poor prognosis and limited treatment options due to late-stage ...
Mahdi Zahmatyar, Ladan Kharaz, Negin Abiri Jahromi, Ali Jahanian, Pourya Shokri, Seyed Aria Nejadghaderi   +5 more
doaj   +1 more source

Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma

BMC Health Services Research, 2023
Background Immune checkpoint inhibitors (ICIs) and targeted treatments have improved the health outcomes of patients with advanced melanoma. However, due to the high cost of novel therapies, it is crucial to evaluate their value by considering both ...
Si Ni Li, Xiaomin Wan, Liu Bao Peng, Ya Min Li, Jian He Li   +4 more
doaj   +1 more source

Identification of BRAF V600E Mutation in Cerebrospinal Fluid Aids in Diagnosing Leptomeningeal Carcinomatosis Arising From Pleomorphic Xanthoastrocytoma: A Case Report

Cancer Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Pleomorphic xanthoastrocytomas (PXAs) are rare primary central nervous system (CNS) tumors that appear heterogeneous on imaging and histology and typically cause headaches or seizures on initial presentation. Alongside high rates of favorable prognosis after surgical excision exist similarly high rates of recurrence.
Randy S. D'Amico, Patricia Avancena, Alon Kashanian, Rosivel Galvez, Deborah Gruber, Sami Saba, Avraham Zlochower, Manju Harshan, Morana Vojnic   +8 more
wiley   +1 more source

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 802-811, March 2026.
A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner, Pauline Dürr, Phyllis Lensker, Katja Gessner, Lisa Cuba, Rainer Fietkau, Markus F. Neurath, Bernd Wullich, Marianne Pavel, Carola Berking, Matthias W. Beckmann, Andreas Mackensen, Frank Dörje, Martin F. Fromm   +13 more
wiley   +1 more source

Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy

Biomedicines, 2022
Novel targeted therapies for metastatic colorectal cancer are needed to personalize treatments by guiding specific biomarkers selected on the genetic profile of patients. RAS and BRAF inhibitors have been developed for patients who become unresponsive to
Gerardo Rosati, Giuseppe Aprile, Alfredo Colombo, Stefano Cordio, Marianna Giampaglia, Alessandro Cappetta, Concetta Maria Porretto, Alfonso De Stefano, Domenico Bilancia, Antonio Avallone   +9 more
doaj   +1 more source